PTEN-dependent changes of gene expressions in human prostate tumors

  • G. V. Gerashchenko
  • O. V. Grygoruk
  • L. V. Mevs
  • V. I. Kashuba
DOI: https://doi.org/10.7124/FEEO.v22.934

Abstract

Aim. To determine the levels of PTEN relative expression (RE) and the possible effects of its loss on some tumor-associated genes and histological characteristics of human prostate tumors. Methods. PTEN RE and 46 genes were identified in 37 pairs of adenocarcinoma and conventionally normal tissues (CNT) and 20 adenomas by real time PCR. Results. We are shown PTEN RE decreasing in the adenocarcinoma group as well as in CNTs compared with adenomas. 54 % of adenocarcinomas, 48.6 % of CNT and 25 % of adenomas were detected with low PTEN RE. We have found 9 of 46 differentially expressed genes in groups with different levels of PTEN RE (ESR1, GCR, KRT18, MMP2, MMP9, SRD5A2, VIM, PCA3, HOTAIR). It was revealed some histological characteristics correlated with PTEN RE in prostate adenocarcinomas. Conclusions. PTEN aberrations in prostate tumors indicate that PTEN associated changes already have been occurred at the benign tumors. We have shown some tumor histological characteristics associated with PTEN expression changes.
Keywords: prostate tumors, relative gene expression, PTEN, EMT, histological characteristics.

References

Ortega-Molina A., Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 2013. Vol. 24. P. 184–189. doi: 10.1016/j.tem.2012.11.002.

Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009. Vol. 4. P. 127–150. doi: 10.1146/annurev.pathol.4.110807.092311.

Ferraldeschi R., Nava Rodrigues D., Riisnaes R., Miranda S., Figueiredo I., Rescigno P., Ravi P., Pezaro C., Omlin A., Lorente D., Zafeiriou Z., Mateo J., Altavilla A., Sideris S., Bianchini D., Grist E., Thway K., Perez Lopez R., Tunariu N., Parker C., Dearnaley D., Reid A., Attard G., de Bono J. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015. Vol. 4. P. 795–802. doi: 10.1016/j.eururo.2014.10.027.

Ahearn T.U., Pettersson A., Ebot E.M., Gerke T., Graff R.E., Morais C.L., Hicks J.L., Wilson K.M., Rider J.R., Sesso H.D., Fiorentino M., Flavin R., Finn S., Giovannucci E.L., Loda M., Stampfer M.J., De Marzo A.M., Mucci LA., Lotan T.L. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2015. Vol. 108. pii: djv346. doi: 10.1093/jnci/djv346.

Gerashchenko G.V., Mankovska O.S., Dmitriev A.A., Mevs L.V., Rosenberg E.E., Pikul M.V., Marynychenko M.V., Gryzodub O.P., Stakhovsky E.O., Kashuba V.I. Expression of epithelial-mesenchymal transition-related genes in prostate tumours. Biopolymers and Cell. 2017. Vol. 33. No. 5. P. 335–355. doi: http://dx.doi.org/10.7124/bc.00095E.

Mevs L.V., Gerashchenko G.V., Rosenberg E.E., Pikul M.V., Marynychenko M.V., Gryzodub O.P., Vozianov S.O., Stakhovsky E.O., Kashuba V.I. Detection of prostate specific ETS fusion transcripts in cancer samples. Biopolymers and Cell. 2017. V. 33. P. 256-267. doi: http://dx.doi.org/10.7124/bc.000958.

Gerashchenko G.V., Mevs L.V., Chashchina L.I., Pikul M.V., Gryzodub O.P., Stakhovsky E.O., Kashuba V.I. Expression of steroid and peptide hormone receptors, metabolic enzymes and emt-related genes in prostate tumors in relation to presence of the TMPRSS2/ERG fusion. Exp Oncol. 2018. Vol. 40(2). P.101-108

Lahdensuo K., Erickson A., Saarinen I., Seikkula H., Lundin J., Lundin M., Nordling S., Bützow A., Vasarainen H., Boström P.J., Taimen P., Rannikko A., Mirtti T. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Mod Pathol. 2016. Vol. 12. P. 1565–1574. doi: 10.1038/modpathol.2016.154.

Teixeira A, Marchit S, Emmanuel Dias-Neto E, Nunes D.N., da Silva I.T., Chackerian B., Barry M., Lauer R.C., Giordano R.J., Sidman R.L., Wheeler C.M., Cavenee W.K., Pasqualini R., Arap W. Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses. EMBO Molecular Medicine. 2017. Vol. 9. P. 1327–1330. doi: 10.15252/emmm.201708072.